文献速递胸部肿瘤放疗放疗物理与技术姑息放疗与转移瘤

基于镓-68灌注PET/CT功能映射的剂量体积参数预测肺SBRT后健康相关生活质量

Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT.
PubMed 文献 · Radiat Oncol · 2025-07-09

PEGASUS试验的预设探索性终点分析,评估肺立体定向体部放疗(SBRT)对健康相关生活质量(HRQoL)的影响。单中心前瞻性研究纳入60例原发或继发肺肿瘤患者,用EORTC QLQ-C30等量表在基线和放疗后12个月内多次评估。单因素分析显示功能肺体积剂量与HRQoL早期和晚期恶化显著相关,而解剖肺参数无此关联。

要点

  • 功能肺体积的PET剂量参数与SBRT后HRQoL下降显著相关。
  • 解剖肺参数与HRQoL变化无显著关联。
  • 灌注PET/CT引导的功能肺规避计划可能改善HRQoL。

核心结论

  • 功能肺体积的PET剂量参数升高与HRQoL下降显著相关,而解剖肺参数无此关联。
  • 灌注PET/CT引导的功能肺规避计划可能是改善肺SBRT患者HRQoL的简单无创方法。

研究设计与样本

  • 单中心前瞻性研究,纳入计划接受SBRT的原发或继发肺肿瘤患者60例。
  • HRQoL用EORTC QLQ-C30、QLQ-LC13和EQ-5D-5L在首次访视、SBRT后1个月、3个月及每3个月至12个月评估。
  • 可分析早期(1-3个月)39例,晚期(6-12个月)22例。
  • 探索性分析基线HRQoL、患者和SBRT相关特征(含PET灌注功能参数)对HRQoL变化的影响,采用单因素分析。

主要发现

  • 13例(33%)患者出现QoL恶化(早期可分析人群)。
  • 7例(32%)患者出现QoL恶化(晚期可分析人群)。
  • 单因素分析中,心脏最大剂量、功能肺体积剂量和肺功能检查参数与HRQoL早期恶化显著相关。
  • 仅功能肺体积剂量与HRQoL晚期恶化显著相关。

临床怎么用

  • 在肺SBRT计划中可考虑使用灌注PET/CT功能映射评估功能肺体积剂量,以辅助预测和改善HRQoL。

局限性

  • 单中心前瞻性研究,样本量有限(可分析早期39例、晚期22例)。
  • HRQoL分析为探索性终点,采用单因素分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PEGASUS trial was the first study to evaluate and demonstrate the benefits of 68Ga-perfusion PET/CT in the lung stereotactic body radiotherapy (SBRT) planning process in preserving functional lung volumes while respecting target volume coverage and doses to other organs at risk. Here we report the prespecified exploratory endpoint of SBRT on health-related quality of life (HRQoL). METHODS: In this single-center prospective study, we recruited patients planned to be treated in our radiotherapy department with SBRT for primary or secondary lung tumors. Patient-reported outcomes were assessed at the first visit, 1 month, 3 months and every 3 months until 12 months after SBRT using the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30), the EORTC Quality of Life Questionnaire Lung Cancer 13 items (QLQ-LC13), and the European Quality of Life 5 Dimensions-5 Level (EQ-5D-5 L) questionnaire. The key exploratory HRQoL endpoints (analyzed for all patients who completed at least QLQ-C30 at least one time point after SBRT) were baseline-to-early change (between 1 month and 3 month) and baseline-to-late change (between 6 month and 12 month) in the QLQ-C30 global health status (GHS)/quality-of-life (QoL) score and in the deterioration of the dyspnea (patient-reported lung toxicity). Explorative analysis of the impact of baseline HRQoL, patient- and SBRT-related characteristics, including PET perfusion-based functional parameters, on the change in HRQoL from baseline was analyzed using univariate analysis. RESULTS: Of the 60 patients included, 39 were analyzable as early-onset and 22 as late-onset. Thirteen (33%) and 7 (32%) patients had a deterioration of QoL. In univariate analysis, maximal dose to the heart, doses to the functional lung volume and pulmonary functional test parameters were significantly associated with the early deterioration of HRQoL. Only doses to the functional lung volume were significantly associated with the late deterioration of HRQoL. CONCLUSION: In our study, increased radiation doses in functional lung volume PET bases dose parameters were significantly associated with a decrease of HRQoL unlike anatomic lung parameters. Functional lung avoidance planning guided by perfusion PET/CT may be a simple and noninvasive method to improve HRQoL in patients treated with lung SBRT.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lucia F, Lamour J, Geier M, et al. Prediction of health-related quality-of-life results after lung stereotactic body radiotherapy using dose-volume parameters from functional mapping on Gallium-68 perfusion PET/CT. Radiat Oncol. 2025. PMID: 40635037. doi:10.1186/s13014-025-02685-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。